{"groups":[{"description":"Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRecombinant EphB4-HSA Fusion Protein: Given IV","id":"FG000","title":"Treatment (sEphB4-HSA, Azacitidine, Decitabine)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study has no pre-assignment. All participants were given the same treatment.","recruitmentDetails":"Recruitment for this study started in April 2017 and ended in March 2019 due to lack of funding. All participants were seen and treated at University of Southern California Norris Comprehensive Cancer Center and/or Los Angeles County+University of Southern California Medical Center."}